Ruxolitinib After Hematopoietic Stem Cell Transplant (HSCT)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study is enrolling people who have developed lung problems (called Bronchiolitis Obliterans or BO) after hematopoietic stem cell transplant (HSCT). BO is a type of lung injury after HSCT due to graft versus host disease. While BO is uncommon after HSCT, when BO occurs it is often diagnosed late in patients, when lung injury is hard to treat and can be irreversible, leading to long-term lung disease or even death.

The purpose of this study is to find out more about a drug called ruxolitinib (the "study drug") as an early treatment for lung injury and BO after HSCT.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT04908735

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
22-020584
Official Title:
Ruxolitinib for Early Lung Dysfunction after HSCT: A Phase II Study
Study Phase:
Phase II
Eligible Age Range:
5 - 60 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in this research, you will:

  • Take the study drug, ruxolitinib, by mouth twice a day for 24 weeks (about 6 months)
  • Complete frequent clinic visits at CHOP Philadelphia
  • Have research DXA scans
  • Have research pulmonary tests (oscillometry and home spirometry)
  • Have frequent blood tests
  • Submit biological samples (including blood, stool, urine, and more) to a biorepository at Cincinnati Children's Hospital Medical Center (CCHMC, the lead research site)
  • Have research genetic tests
  • Complete a study medication diary
Leader
Timothy S. Olson Headshot

Timothy S. Olson, MD, PhD